Feasibility of Very High Cumulative Equivalent Dose in 2 Gy Fraction in Locally Advanced Central/Ultracentral Nonsmall Cell Lung Cancer Treated With Conventional Chemoradiation Therapy and a Stereotactic Boost
The following preliminary dose constraints-PBV tree D1cc < 150 Gy *2* and esophageal D1cc < 100 Gy *10*-may be safe and are currently being prospectively evaluated in an ongoing phase 2 trial (NCT06627738). The correlation between toxicities and the degree of initial tumor infiltration of organs at risk requires further prospective evaluation.
Authors
- Baptiste Lhomel
- Médéric Barret
- Anna Gueiderikh (ORCID: https://orcid.org/0000-0002-2871-5476)
- Pierre‐Yves Bondiau
- A.O. Naghavi (ORCID: https://orcid.org/0000-0002-0884-1942)
- Victoria Ferrari (ORCID: https://orcid.org/0000-0002-4403-1808)
- J. Doyen (ORCID: https://orcid.org/0000-0003-4646-4778)
- Renaud Schiappa (ORCID: https://orcid.org/0000-0001-5104-9507)
- Bastien Chanoux
Institutions
- Moffitt Cancer Center (US)
- Centre Antoine Lacassagne (FR)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1016/j.adro.2025.101925
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00